If weight goes up and down, up and down, metabolically it sets people up for functional decline down the road. Of course, in considering why patients discontinue, a large part of it is money, Emanuel said
In a real-world cohort, six-month semaglutide loss was about 8.8%, roughly 0.6 to 0.8 of the STEP figure, mostly through adherence and persistence rather than a weaker drug. Read the trial number as a ceiling to translate down toward your own body and your own consistency, not as a forecast
Damian GuerreroELopez-VelazquezAMAhlawatJNarayanM
They are approved for type 2 diabetes management and obesity treatment in patients meeting specific BMI criteria, but their use for lipedema represents off-label prescribing with limited clinical evidence
Intriguingly, GOS upregulated IL-10 more effectively than Citalopram, a selective serotonin reuptake inhibitor (Miranda et al., 2025) highlighting its therapeutic promise via the MGBA pathway
not known: myasthenia, muscle tension